Pliant Market Capitalization from 2010 to 2024
PLRX Stock | USD 13.46 0.48 3.70% |
Check Pliant Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pliant Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 1.3 M, Net Interest Income of 20.2 M or Interest Income of 21.5 M, as well as many indicators such as Price To Sales Ratio of 707, Dividend Yield of 0.0 or PTB Ratio of 2.36. Pliant financial statements analysis is a perfect complement when working with Pliant Therapeutics Valuation or Volatility modules.
Pliant | Market Capitalization |
Latest Pliant Therapeutics' Market Capitalization Growth Pattern
Below is the plot of the Market Cap of Pliant Therapeutics over the last few years. It is Pliant Therapeutics' Market Cap historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Pliant Therapeutics' overall financial position and show how it may be relating to other accounts over time.
View | Last Reported 789.88 M | 10 Years Trend |
|
Market Cap |
Timeline |
Pliant Market Capitalization Regression Statistics
Arithmetic Mean | 368,643,557 | |
Geometric Mean | 98,002,652 | |
Coefficient Of Variation | 116.56 | |
Mean Deviation | 377,228,178 | |
Median | 17,114,486 | |
Standard Deviation | 429,683,811 | |
Sample Variance | 184628.2T | |
Range | 1.1B | |
R-Value | 0.89 | |
Mean Square Error | 40546.5T | |
R-Squared | 0.80 | |
Slope | 85,725,692 | |
Total Sum of Squares | 2584794.5T |
Pliant Market Capitalization History
About Pliant Therapeutics Financial Statements
Pliant Therapeutics investors use historical fundamental indicators, such as Pliant Therapeutics' Market Capitalization, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Pliant Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California. Pliant Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 110 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Pliant Stock Analysis
When running Pliant Therapeutics' price analysis, check to measure Pliant Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pliant Therapeutics is operating at the current time. Most of Pliant Therapeutics' value examination focuses on studying past and present price action to predict the probability of Pliant Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pliant Therapeutics' price. Additionally, you may evaluate how the addition of Pliant Therapeutics to your portfolios can decrease your overall portfolio volatility.